Enliven Therapeutics (ELVN) Operating Income Growth (3y) (2022 - 2026)
Enliven Therapeutics (ELVN) Operating Income Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | 16.96% |
| 2 | Nanobiotix | 1,880.51 Bn | 1,880.45 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.94 Bn | 463.15 Bn | 1.35 Bn | 38.78% |
| 5 | Vertex Pharmaceuticals | 122.63 Bn | 115.38 Bn | 2.59 Bn | 13.47% |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.54 Bn | 3.31 Bn | -12.10% |
| 7 | Belite Bio | 62.81 Bn | 62.81 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.59 Bn | 1.41 Bn | 69.02% |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 55.96% |
| 10 | Enliven Therapeutics | 3.40 Bn | 2.95 Bn | - | -19.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.22% |
| Dec 31, 2025 | -49.98% |
| Sep 30, 2025 | -31.91% |
| Jun 30, 2025 | -46.90% |
| Mar 31, 2025 | -54.00% |
| Dec 31, 2024 | -23.34% |
| Sep 30, 2024 | -25.61% |
| Jun 30, 2024 | -23.16% |
| Mar 31, 2024 | -36.22% |
| Dec 31, 2023 | -25.31% |
| Sep 30, 2023 | -24.74% |
| Jun 30, 2023 | -25.03% |
| Mar 31, 2023 | -30.71% |
| Dec 31, 2022 | -10.74% |
| Sep 30, 2022 | -16.69% |
| Jun 30, 2022 | -17.51% |
| Mar 31, 2022 | -27.43% |